CSF1R sirna

CSF1R siRNA (Mouse)

Cat. Num. AAA8216593

• Gene Names: Csf1r; Fms; CD115; Csfmr; Fim-2; CSF-1R; M-CSFR; M-CSF-R; AI323359
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: CSF1R; CSF1R siRNA (Mouse); CSFMR; FMS; Macrophage colony-stimulating factor 1 receptor; CSF-1 receptor; CSF-1-R; CSF-1R; M-CSF-R; Proto-oncogene c-Fms; CD antigen CD115; CSF1R sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: CSF1R siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 977

• Applicable Applications for CSF1R sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse CSF1R gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for CSF1R sirna

siRNA to inhibit CSF1R expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 126723423
• NCBI GeneID: 12978
• NCBI Accession #: NP_001032948.2
• NCBI GenBank Nucleotide #: NM_001037859.2
• UniProt Accession #: P09581; Q3U3P1; Q9DBH9
• Molecular Weight: 109,179 Da
• NCBI Official Full Name: macrophage colony-stimulating factor 1 receptor
• NCBI Official Synonym Full Names: colony stimulating factor 1 receptor
• NCBI Official Symbol: Csf1r
• NCBI Official Synonym Symbols: Fms; CD115; Csfmr; Fim-2; CSF-1R; M-CSFR; M-CSF-R; AI323359
• NCBI Protein Information: macrophage colony-stimulating factor 1 receptor
• UniProt Protein Name: Macrophage colony-stimulating factor 1 receptor
• Protein Family: Macrophage colony-stimulating factor 1 receptor
• UniProt Gene Name: Csf1r
• UniProt Synonym Gene Names: Csfmr; Fms; CSF-1-R; CSF-1R; M-CSF-R
• UniProt Entry Name: CSF1R_MOUSE

Uniprot Description

CSFR: an oncogenic tyrosine kinase receptor for CSF-1 (M-CSF). Drives growth and development of monocytes. Binding of CSF-1 induces receptor dimerization, activation and autophosphorylation of cytoplasmic tyrosine residues used as docking sites for SH2-containing signaling proteins. There are at least five major tyrosine autophosphorylation sites. Two point mutations seen in 10-20% of patients with acute myeloid leukemia, chronic myelomonocytic leukemia or myelodysplasia. One mutation appears to be both somatic and germline, and disrupts Cbl binding and receptor turnover. v-fms lacks the Cbl binding site and causes feline leukemia. Mutations may also develop after chemotherapy for lymphoma. A distinct point mutation was found in some cases of hepatocellular carcinoma and related to increased expression, and another mutation was found in 2 of 40 patients with idiopathic myelofibrosis. Expression is elevated in breast tumors and cell lines, and expression in xenografts and transgenic mice has been correlated with xenograft growth and breast cancer development. Inhibitors: Ki-20227 and other Kit/PDGFR inhibitors.

Protein type: Kinase, protein; Protein kinase, tyrosine (receptor); EC 2.7.10.1; Membrane protein, integral; Protein kinase, TK; Oncoprotein; TK group; PDGFR family

Cellular Component: cell surface; membrane; plasma membrane; integral to membrane; intracellular; receptor complex

Molecular Function: macrophage colony stimulating factor receptor activity; protein homodimerization activity; nucleotide binding; transmembrane receptor protein tyrosine kinase activity; protein phosphatase binding; protein kinase activity; transferase activity; protein binding; cytokine binding; protein-tyrosine kinase activity; transferase activity, transferring phosphorus-containing groups; kinase activity; ATP binding

Biological Process: regulation of bone resorption; phosphoinositide-mediated signaling; peptidyl-tyrosine phosphorylation; immune system process; positive regulation of osteoclast differentiation; cytokine and chemokine mediated signaling pathway; protein amino acid autophosphorylation; osteoclast differentiation; protein amino acid phosphorylation; positive regulation of tyrosine phosphorylation of Stat3 protein; cell proliferation; regulation of cell shape; positive regulation of cell proliferation; ruffle organization and biogenesis; innate immune response; hemopoiesis; positive regulation of protein amino acid phosphorylation; phosphatidylinositol metabolic process; inflammatory response; intercellular junction maintenance; phosphorylation; transmembrane receptor protein tyrosine kinase signaling pathway; positive regulation of cell migration